Reported Earnings • May 24
First quarter 2026 earnings released: zł0.60 loss per share (vs zł0.94 loss in 1Q 2025) First quarter 2026 results: zł0.60 loss per share (improved from zł0.94 loss in 1Q 2025). Revenue: zł4.57m (up 68% from 1Q 2025). Net loss: zł9.74m (loss narrowed 36% from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance. 공고 • Aug 25
Mabion S.A. to Report First Half, 2025 Results on Sep 30, 2025 Mabion S.A. announced that they will report first half, 2025 results on Sep 30, 2025 공고 • Apr 25
Mabion S.A., Annual General Meeting, May 26, 2025 Mabion S.A., Annual General Meeting, May 26, 2025. Valuation Update With 7 Day Price Move • Nov 05
Investor sentiment deteriorates as stock falls 27% After last week's 27% share price decline to €2.55, the stock trades at a trailing P/E ratio of 18.9x. Average trailing P/E is 24x in the Biotechs industry in Europe. Total loss to shareholders of 84% over the past three years. Reported Earnings • Oct 29
Third quarter 2024 earnings released: zł1.01 loss per share (vs zł0.67 profit in 3Q 2023) Third quarter 2024 results: zł1.01 loss per share (down from zł0.67 profit in 3Q 2023). Revenue: zł516.0k (down 98% from 3Q 2023). Net loss: zł16.3m (down 250% from profit in 3Q 2023). Revenue is expected to decline by 11% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 21%. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings. Reported Earnings • Sep 11
Second quarter 2024 earnings released Second quarter 2024 results: Revenue: zł29.8m (down 17% from 2Q 2023). Net income: zł10.3m (down 33% from 2Q 2023). Profit margin: 35% (down from 42% in 2Q 2023). Revenue is expected to decline by 4.2% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 20%. Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings. New Risk • Sep 03
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 100% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 100% per year for the foreseeable future. High level of non-cash earnings (128% accrual ratio). Minor Risk Market cap is less than US$100m (€71.8m market cap, or US$79.2m). New Risk • Jul 16
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 112% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 112% per year for the foreseeable future. High level of non-cash earnings (128% accrual ratio). Minor Risk Market cap is less than US$100m (€66.5m market cap, or US$72.4m). 공고 • May 25
Mabion S.A., Annual General Meeting, Jun 17, 2024 Mabion S.A., Annual General Meeting, Jun 17, 2024. Reported Earnings • May 19
First quarter 2024 earnings released: EPS: zł1.06 (vs zł1.02 in 1Q 2023) First quarter 2024 results: EPS: zł1.06 (up from zł1.02 in 1Q 2023). Revenue: zł34.0m (down 14% from 1Q 2023). Net income: zł17.5m (up 6.5% from 1Q 2023). Profit margin: 52% (up from 42% in 1Q 2023). Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • May 14
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to €4.28, the stock trades at a trailing P/E ratio of 7.1x. Average trailing P/E is 31x in the Biotechs industry in Europe. Total loss to shareholders of 57% over the past three years. Reported Earnings • Apr 18
Full year 2023 earnings released: EPS: zł2.55 (vs zł1.44 in FY 2022) Full year 2023 results: EPS: zł2.55 (up from zł1.44 in FY 2022). Revenue: zł151.7m (down 7.5% from FY 2022). Net income: zł41.3m (up 78% from FY 2022). Profit margin: 27% (up from 14% in FY 2022). The increase in margin was driven by lower expenses. Revenue is expected to decline by 1.1% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 18%. Over the last 3 years on average, earnings per share has increased by 103% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings. New Risk • Dec 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 28% per year for the foreseeable future. High level of non-cash earnings (34% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Market cap is less than US$100m (€84.4m market cap, or US$91.3m). Valuation Update With 7 Day Price Move • Nov 29
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to €4.80, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 25x in the Biotechs industry in Europe. Total returns to shareholders of 7.0% over the past year. New Risk • Nov 17
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 34% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 18% per year for the foreseeable future. High level of non-cash earnings (34% accrual ratio). Minor Risk Market cap is less than US$100m (€65.7m market cap, or US$71.2m). Reported Earnings • Sep 14
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: zł36.0m (down 18% from 2Q 2022). Net income: zł15.2m (up 198% from 2Q 2022). Profit margin: 42% (up from 12% in 2Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany. 공고 • Jun 13
Mabion S.A., Annual General Meeting, Jun 13, 2023 Mabion S.A., Annual General Meeting, Jun 13, 2023, at 14:00 Central European Standard Time. Valuation Update With 7 Day Price Move • Aug 11
Investor sentiment deteriorated over the past week After last week's 21% share price decline to €5.64, the stock trades at a trailing P/E ratio of 16.1x. Average forward P/E is 25x in the Biotechs industry in Europe. Total loss to shareholders of 62% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €2.51 per share. Valuation Update With 7 Day Price Move • Jul 18
Investor sentiment deteriorated over the past week After last week's 16% share price decline to €6.22, the stock trades at a trailing P/E ratio of 18.2x. Average forward P/E is 30x in the Biotechs industry in Europe. Total loss to shareholders of 50% over the past year. Valuation Update With 7 Day Price Move • Jul 02
Investor sentiment improved over the past week After last week's 16% share price gain to €5.28, the stock trades at a trailing P/E ratio of 15x. Average forward P/E is 32x in the Biotechs industry in Europe. Total loss to shareholders of 64% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €2.41 per share. Valuation Update With 7 Day Price Move • Jun 15
Investor sentiment deteriorated over the past week After last week's 27% share price decline to €4.51, the stock trades at a trailing P/E ratio of 12.7x. Average forward P/E is 31x in the Biotechs industry in Europe. Total loss to shareholders of 74% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €2.47 per share. 공고 • May 27
Mabion S.A., Annual General Meeting, Jun 21, 2022 Mabion S.A., Annual General Meeting, Jun 21, 2022, at 11:00 Central European Standard Time. Breakeven Date Change • Apr 27
Forecast breakeven date moved forward to 2022 The analyst covering Mabion previously expected the company to break even in 2023. New forecast suggests the company will make a profit of zł59.0m in 2022. Average annual earnings growth of 69% is required to achieve expected profit on schedule. Breakeven Date Change • Jul 27
Forecast breakeven moved forward to 2022 The 2 analysts covering Mabion previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of zł59.0m in 2022. Average annual earnings growth of 63% is required to achieve expected profit on schedule.